ABSTRACT
@#ObjectiveTo explore the protective effect of Sox11 gene on cerebral ischemia reperfusion injury(CIRI)in mice and its mechanism,so as to provide a new target for the treatment of CIRI.MethodsThe mouse middle cerebral artery occlusion(MCAO)model and Neuro2A cell oxygen glucose deprivation reperfusion(OGDR)model were established and detected for the temporal and spatial distribution of Sox11 in the models by real-time quantitative PCR,Western blot,immunohistochemistry(IHC)and immunohistofluorescence(IHF).The altered expression of some crucial genes in the pathway of apoptosis and inflammation in OGDR model after the disruption of Sox11 expression was detected by Western blot.ResultsThe expression level of Sox11 mRNA and protein increased significantly in both MCAO and Neuro2A OGDR models(P = 0.000 1 ～ 0.038 8);After CIRI,Sox11 expression was elevated in the hippocampal dentate gyrus(DG)region of mice;After interfering with the expression of Sox11 in OGDR model,the expression of apoptosis-related protein Cleaved Caspase 3 significantly increased,while the expression of anti-apoptosis protein Bcl-2 significantly decreased,and the expression of phosphorylated NF-κB(p-NF-κB)protein related to inflammatory reaction also up-regulated significantly.Conclusion Sox11gene had a protective effect against CIRI in mice,and was involved in the regulation of apoptosis and inflammation pathways after CIRI.
ABSTRACT
Objective: To detect the methylation status of SOX11 gene in normal cervix, cervical cancer tissues and cervical cancer cell lines so as to explore the relationship between methylation status and expression of SOX11 gene. Methods: DNA methylation status of SOX11 gene in normal cervical, cervical cancer tissues and cervical cancer cell lines was analyzed by bisulfite sequencing and TA cloning assay. The expression of SOX11 mRNA in cervical cancer tissues, cell lines and normal cervical was detected by RT-PCR. Results: The average methylation rate of SOX11 in cervical cancer tissues (81.07%) was significantly higher than that in normal cervical tissues (12.86%) (P<0.001). The methylation status of SOX11 in HeLa, SiHa, C33-A and CaSki cells was all hypermethylated with the methylation of 90.71%, 97.14%, 77.14% and 99.64%, respectively. The expression of SOX11 mRNA in cervical cancer tissues was significantly lower than that in normal cervixes (P<0.001). The SOX11 gene expression was significantly negatively correlated with its promoter hypermethylation (P<0.001, r=-0.808). After demethylation agent 5-azacytidine treatment, SOX11 mRNA expression in cervical cancer cell lines was significantly increased. Further analysis showed that HPV infection in cervical cancer might increase SOX11 promotor methylation. Conclusion: SOX11 gene in cervical cancer is silenced by the hypermethylation of DNA in the promoter region.
ABSTRACT
Objective To explore the expression level of Sox11 gene in cervical cancer cell lines and cervical pathology tissue .Methods The expression of Sox11 protein was detected in cervical cancer cell lines HeLa , CaSki ,SiHa and C-33A as well as NC ,LSIL ,HSIL and CC using immunohistochemistry and Western blot .We analyzed the relationship between Sox11 expression in cervical cancer and clinicopathologic parameters .Results The expression of Sox11 protein in normal cervical tissue ,low-grade cervical squamous intraepithelial neoplasia was significantly higher than that in the high-grade cervical squamous intraepithelial neoplasia and invasive cervical cancer tissue , and the expression was reduced with the progression of cervical lesions .The expression of Sox11 protein in the invasive cervical cancer was reduced with increased malignant degree .The expression of Sox11 protein in the invasive cervical cancer was significantly correlated with HPV infection ,but not associated with the age , clinical stage ,lymph node metastasis or muscular infiltration depth .Conclusion Sox11 expression is negatively correlated with cervical cancer development ,suggesting that as a tumor suppressor gene ,Sox11 may play a role in cervical cancer development and its absence or low expression is associated with the development of cervical cancer and is an early event of cervical carcinogenesis and may be a sign of malignant change of cervical tissue .
ABSTRACT
El gen SOX11, perteneciente a la familia de genes SOXC, es un factor de transcripción involucrado en la neurogénesis embrionaria y el remodelado tisular, participando asimismo en el control de la proliferación celular. Su rol en la linfomagénesis es desconocido. Estudios recientes han mostrado expresión proteica nuclear aberrante y sobreexpresión de los niveles de transcripto de SOX11 en pacientes con linfoma de células del manto (LCM). Si bien la mayoría de estos linfomas presentan un curso clínico agresivo, existe un subgrupo de pacientes con enfermedad indolente, sugiriendo una mayor heterogeneidad de esta patología. Actualmente, existen contradicciones respecto de la asociación entre la expresión del gen SOX11 y la evolución clínica del LCM; mientras algunos autores relacionan la ausencia de expresión de SOX11 con buen pronóstico, otros lo encuentran asociado a un curso clínico adverso. Esta diferencia en la expresión estaría relacionada a mecanismos epigenéticos, metilación del ADN y modificaciones a nivel de histonas, que permitirían la expresión aberrante de este gen en algunas neoplasias linfoides, incluyendo LCM. La profundización del conocimiento del gen SOX11 en LCM hará factible, sin duda, lograr una mayor comprensión de los mecanismos involucrados en la patogénesis y/o progresión de este linfoma, así como del rol de SOX11 en estos procesos.
SOX11, belonging to the family of genes SOXC, is a transcript factor involved in the embryonic neurogenesis and tissue remodeling, also participating in the control of cell proliferation. Its role in lymphomagenesis still remains unknown. Recent studies have shown aberrant SOX11 nuclear protein expression as well as mRNA levels in patients with mantle cell lymphoma (MCL). Although the majority of these lymphomas have an aggressive clinical course, there is a subgroup of patients with an indolent clinical evolution, suggesting a greater heterogeneity of this disease. Currently, there are contradictions regarding the association of SOX11 gene expression and outcome in MCL, while some authors have related the lack of SOX11 expression with good prognosis, others find it associated with an adverse clinical course. This difference in the gene expression could be associated to epigenetic mechanisms such as modifications at the histone level and DNA methylation that would allow the aberrant expression of this gene in some lymphoid neoplasias, including LCM. More knowledge of gene SOX11 in LCM will lead to a greater understanding of those mechanisms involved in the pathogenesis and progression of this lymphoma, also the involvement of SOX11 in these processes.